Approved for: SCLC

Lurbinectedin was approved for Small Cell Lung Cancer (SCLC) that is metastatic. It is used in adults whose disease has gotten worse during or after treatment with platinum chemotherapy. This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that lurbinectedin provides a clinical benefit in these patients.